Summary
RXK3 Chart
SELLAS Life Sciences Group, Inc. (SLS) Discusses Innovation in AML Treatments With Focus on GPS and SLS009 Programs Transcript
SELLAS Life Sciences Group, Inc. ( SLS ) Discusses Innovation in AML Treatments With Focus on GPS and SLS009 Programs October 29, 2025 10:00 AM EDT Company Participants Angelos Stergiou - Founder, President, CEO & Director Dragan Cicic - Senior VP & Chief Development Officer Conference Call Participants Dr. Omer Jamy Dr. Panagiotis Tsirigotis Dr. Philip M. Ryan Sharif Khan, M.D.
Sellas Life Sciences: SLS009's Phase 2 Sets Up A Promising 2026
SELLAS Life Sciences is developing GPS as a WT1 immunotherapy, which is in Phase 3 for AML. However, I believe their SLS009 candidate as a CDK9 inhibitor further gives the stock broad AML applicability. GPS's REGAL final analysis at 80 events expected should come by year-end 2025. Its prior data suggest survival advantages versus historical controls.
SELLAS Life Sciences Group (SLS) Upgraded to Buy: What Does It Mean for the Stock? (Revised)
SELLAS Life Sciences Group (SLS) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Sellas Life Sciences Group Inc. (RXK3) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Sellas Life Sciences Group Inc. ever had a stock split?
Sellas Life Sciences Group Inc. Profile
| Biotechnology Industry | Healthcare Sector | Angelos M. Stergiou ScD h.c. CEO | XFRA Exchange | US81642T2096 ISIN |
| US Country | 15 Employees | - Last Dividend | 8 Nov 2019 Last Split | 29 Dec 2017 IPO Date |
Overview
SELLAS Life Sciences Group, Inc. is a distinguished late-stage clinical biopharmaceutical company with a focused aim on the advancement of innovative cancer immunotherapies across a multitude of cancer indications within the United States. The company is engaged in pioneering the development of novel therapeutic agents that have the potential to significantly improve the treatment landscape for patients battling various forms of cancer. Through its strategic collaborations with industry leaders like Merck & Co., Inc. and GenFleet Therapeutics (Shanghai), Inc., SELLAS is at the forefront of exploring synergistic therapeutic strategies that could enhance the efficacy of its leading product candidate. The company's headquarters are strategically located in New York, New York, signifying its centrality in the biopharmaceutical innovation hub.
Products and Services
- Galinpepimut-S (GPS)
GPS represents a groundbreaking cancer immunotherapeutic agent engineered to target the Wilms tumor 1 (WT1) antigen, a critical molecular target in oncology given its universal overexpression in a wide range of malignant tumors. SELLAS's pioneering approach with GPS encompasses:
- A pivotal Phase 3 clinical trial aimed at acute myeloid leukemia (AML), a formidable challenge in cancer treatment due to its rapid progression and high relapse rates.
- Initiation of Phase 1/2 clinical trials exploring the effectiveness of GPS in treating ovarian cancer, aiming to establish a new therapeutic avenue for managing this often difficult-to-treat malignancy.
- Collaborative Research and Development
In a strategic collaboration with Merck & Co., Inc., SELLAS is engaged in the exploration of GPS in combination with pembrolizumab, a PD1 blocker, within a Phase 1/2 clinical trial. This trial is ambitiously enrolling patients across up to five cancer indications, covering both hematologic malignancies and solid tumors, aiming to harness the combined therapeutic potential of these agents.
- Additionally, the partnership with GenFleet Therapeutics focuses on the development and commercialization of GFH009, a highly selective CDK9 inhibitor. This molecule, currently under a Phase 1 clinical trial, represents another frontier of SELLAS’s exploration into next-generation cancer therapeutics, targeting mechanisms underlying cancer cell proliferation and survival.
Contact Information
